Sirolimus interferes with iron homeostasis in renal transplant recipients

被引:65
|
作者
Maiorano, Annamaria
Stallone, Giovanni
Schena, Antonio
Infante, Barbara
Pontrelli, Paola
Schena, Francesco Paolo
Grandaliano, Giuseppe
机构
[1] Univ Bari, Div Nephrol, Dept Emergency & Transplantat, I-70124 Bari, Italy
[2] Univ Foggia, Div Nephrol, Dept Biomed Sci, Foggia, Italy
关键词
sirolimus; anemia; renal transplantation; hepcidin;
D O I
10.1097/01.tp.0000235545.49391.1b
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Sirolimus is an immunosuppressive drug whose use is frequently associated with anemia. A pathogenic link between sirolimus-induced anemia and the appearance of an inflammatory state was recently suggested. Because inflammation-related anemia is characterized by a functional iron deficiency, we investigated whether sirolimus may influence iron homeostasis and serum levels of hepcidin, a key mediator of inflammation-related-anemia. Methods. To this purpose, 42 consecutive transplanted patients with biopsy-proven chronic allograft nephropathy were randomized (2:1 ratio) to receive either a 40% cyclosporine reduction (group A, 14 patients) or immediate cyclosporine withdrawal and sirolimus introduction (group B, 28 patients). Hemoglobin levels and iron status were evaluated 6 months before and after randomization. Results. The two groups had similar hemoglobin levels and iron status at baseline. We did not observe any significant change in hemoglobin and iron status in group A patients after randomization. On the contrary, we observed a significant reduction of hemoglobin without any change of red blood cell count after sirolimus introduction, with a significant reduction of mean corpuscular volume and mean corpuscular hemoglobin. Serum iron and transferrin saturation (TSAT) levels were markedly reduced after the switch, while ferritin serum concentrations remained stable. Although sirolimus-induced anemia was recently suggested to resemble inflammation-related anemia, hepcidin serum levels were similar in the two groups after randomization. None of group A and eight of group B patients presented a TSAT < 20 and were given iron supplementation after randomization, in all of them oral iron therapy did not influence either hemoglobin or serum iron levels. Conclusion. We demonstrated that sirolimus-induced anemia is independent of the drug antiproliferative effect and does not present the features of inflammation-related anemia. This event maybe due to the direct influence of sirolimus on iron homeostasis.
引用
收藏
页码:908 / 912
页数:5
相关论文
共 50 条
  • [21] Conversion to Sirolimus in Renal Transplant Recipients: A Single-Center Experience
    Yelken, Berna
    Caliskan, Yasar
    Ozkan, Oktay
    Gorgulu, Numan
    Yazici, Halil
    Turkmen, Aydin
    Sever, Mehmet S.
    ARTIFICIAL ORGANS, 2010, 34 (08) : E230 - E237
  • [22] Relationships between sirolimus dosing, concentration and outcomes in renal transplant recipients
    Dansirikul, C
    Duffull, SB
    Morris, RG
    Tett, SE
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (05) : 560 - 565
  • [24] Favorable results of concomitant tacrolimus and sirolimus therapy in Taiwanese renal transplant recipients at 12 months
    Chen, Kuo-Hsin
    Tsai, Meng-Kun
    Lai, I-Rue
    Wu, Fe-Lin Lin
    Hu, Rey-Heng
    Lee, Po-Huang
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2008, 107 (07) : 533 - 539
  • [25] Immunosuppressant Regimen Based on Sirolimus Decreases Aortic Stiffness in Renal Transplant Recipients in Comparison to Cyclosporine
    Joannides, R.
    Monteil, C.
    de Ligny, B. H.
    Westeel, P. F.
    Iacob, M.
    Thervet, E.
    Barbier, S.
    Bellien, J.
    Lebranchu, Y.
    Girardot-Seguin, S.
    Thuillez, C.
    Godin, M.
    Etienne, I.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (11) : 2414 - 2422
  • [26] Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients
    Böttiger, Y
    Brattström, C
    Bäckman, L
    Claesson, K
    Burke, JT
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (05) : 566 - 569
  • [27] Sirolimus therapy in orthotopic liver transplant (OLT) recipients with acute renal insufficiency
    Montalbano, M
    Neff, GW
    Slapak-Green, G
    Berney, T
    Meyer, D
    DIGESTIVE DISEASES AND SCIENCES, 2004, 49 (11-12) : 1986 - 1989
  • [28] Iron deficiency, anemia, and mortality in renal transplant recipients
    Eisenga, Michele F.
    Minovic, Isidor
    Berger, Stefan P.
    Kootstra-Ros, Jenny E.
    van den Berg, Else
    Riphagen, Ineke J.
    Navis, Gerjan
    van der Meer, Peter
    Bakker, Stephan J. L.
    Gaillard, Carlo A. J. M.
    TRANSPLANT INTERNATIONAL, 2016, 29 (11) : 1176 - 1183
  • [29] Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients
    Rogers, Christin C.
    Johnson, Scott R.
    Mandelbrot, Didier A.
    Pavlakis, Martha
    Horwedel, Timothy
    Karp, Seth J.
    Egbuna, Ogo
    Rodrigue, James R.
    Chudzinski, Robyn E.
    Goldfarb-Rumyantzev, Alexander S.
    Hanto, Douglas W.
    Curry, Michael P.
    CLINICAL TRANSPLANTATION, 2009, 23 (06) : 887 - 896
  • [30] Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue
    Butani, L
    TRANSPLANTATION, 2004, 78 (09) : 1362 - 1366